Skip to main content
Shandong Buchang Pharmaceuticals Co., Ltd logo

Shandong Buchang Pharmaceuticals Co., Ltd — Investor Relations & Filings

Ticker · 603858 ISIN · CNE100002FV6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,084 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 603858

About Shandong Buchang Pharmaceuticals Co., Ltd

https://www.buchang.com/

Shandong Buchang Pharmaceuticals Co., Ltd. specializes in the research, development, production, and distribution of medical products, with a primary focus on Modern Traditional Chinese Medicine (TCM). The company focuses on the treatment of cardiovascular and cerebrovascular diseases, offering flagship products such as Danhong Injection, Naoxintong Capsules, and Wenxin Keli. Its portfolio also extends into gynecological, urological, and orthopedic therapeutic areas. By integrating traditional medicinal knowledge with modern scientific research and large-scale manufacturing, the company provides patented formulations aimed at chronic disease management. Its operations encompass the entire value chain from raw material sourcing to clinical research and market distribution, providing integrated healthcare solutions through a diverse range of proprietary formulations.

Recent filings

Filing Released Lang Actions
山东步长制药股份有限公司关于拟转让控股子公司股权及放弃优先受让权的进展公告
Share Issue/Capital Change Classification · 82% confidence The document is a corporate announcement detailing the proposed transfer of equity stakes in a controlling subsidiary, the execution of share transfer agreements, the change in shareholding percentages and the abandonment of pre-emptive rights. It is not a financial report, not management changes, not a financing or dividend notice, and not a repurchase. It describes a change in share capital structure (share transfers) and provides full transaction details. This aligns with “Share Issue/Capital Change (SHA).”
2026-05-29 Chinese
山东步长制药股份有限公司关于为公司控股子公司提供担保的公告
Capital/Financing Update Classification · 85% confidence The document is an announcement by Shandong Buchang Pharmaceutical Co., Ltd. regarding the provision of a guarantee for its controlling subsidiary’s bank loan. It details the guarantee amount, terms, approvals, and cumulative guarantee exposures. This is not a financial statement or regulatory compliance filing but an update on a financing-related action (providing guarantees as part of the company’s financing activities). Therefore, it best fits the Capital/Financing Update category (CAP).
2026-05-28 Chinese
山东步长制药股份有限公司关于控股子公司完成医疗器械经营许可证变更登记的公告
Regulatory Filings Classification · 75% confidence The document is an official announcement by Shandong Buchang Pharma Co., Ltd. regarding its controlling subsidiary’s completion of a change in its medical device operation license registration, including detailed before-and-after license information. It is not a financial report (e.g., 10-K, interim), earnings release, management discussion, proxy statement, or M&A filing. It also does not involve board changes, dividends, share issuances, or legal proceedings. Hence it falls under general regulatory announcements that do not fit other categories, i.e., Regulatory Filings (RNS).
2026-05-26 Chinese
山东步长制药股份有限公司关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 85% confidence The document is an official notice to convene the company’s 2025 annual shareholders’ meeting, detailing the meeting date, agenda items for shareholder voting, voting procedures (including proxy form and online voting instructions), and includes an authorization (proxy) form. This is not the meeting materials themselves or the results, but rather the information statement and proxy solicitation package sent to shareholders to inform them of the AGM and request their votes. Therefore, it fits the Proxy Solicitation & Information Statement category.
2026-05-25 Chinese
山东步长制药股份有限公司关于全资子公司经营范围变更的公告
Regulatory Filings Classification · 85% confidence The document is an announcement regarding a change in the business scope of a wholly-owned subsidiary. It does not contain a full annual or interim report, financial statements, call transcript, management change notice, or other specific category filings. It is a routine regulatory announcement about corporate operations, hence it falls under general Regulatory Filings (RNS).
2026-05-25 Chinese
北京市金杜（青岛）律师事务所关于山东步长制药股份有限公司以集中竞价交易方式回购股份的法律意见书
Transaction in Own Shares Classification · 85% confidence The document is a legal opinion letter (法律意见书) drafted by King & Wood law firm regarding Shandong Buchang Pharmaceutical’s proposed open‐market share repurchase. It reviews approvals, legal compliance, funding sources, and disclosure obligations under PRC company and securities laws. It is not an earnings release, management discussion, or annual/interim report, but directly concerns a share buyback transaction. Under the classification schema, this aligns with “Transaction in Own Shares” (POS: share repurchase/issuance).
2026-05-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.